Business and Trading Update (Shield Therapeutics plc)

) Shield Therapeutics plc ("Shield" or the "Group" or the "Company") Business and trading update London, UK, 15 January 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), provides a business and unaudited trading update for the year ended 31 December 2020. Operational highlights Feraccru® 2020 sales volumes in Europe increased by ~70% year-on-year China IND application submitted First stage of paediatric study plan completed Teva challenge to Shield's European patents withdrawn Shield continues to evaluate options for launching...